Houston didn't even crack the top 100 in the new list. Photo by Alisa Matthews on Unsplash

In a surprise turn of events, Houston has fallen from grace in U.S. News and World Report's "Best Places to Live" ranking for 2023-2024.

Last year, Houston ranked No. 59 on the annual report — not surprising, considering all the Newstonians. However, the Bayou City plummeted to a shocking No. 140. Two years ago, the city ranked as No. 39, so this year's report represents a series of slips for Houston.

But why? According to the report: "A paycheck goes further in Houston than it does in other major metro areas, with affordable housing and free or cheap attractions like biking along Buffalo Bayou and exploring the 7,800-acre George Bush Park. The affordability of this region, which is located in southeastern Texas and home to more than 7 million residents in the metro area, is attracting new people from across the country and around the world."

The report takes a look at several different metrics to determine their rankings, including quality of life, housing affordability, desirability, and job market strength.

Somehow, Houston scored a mere 5.6 out of 10 in the livability score. By the numbers (and out of a perfect 10), Houston scored a 6 for desirability, 6.3 for value, 5.5. for job market, a surprising 5 for quality of life, and 5.9 for net migration.

It gets worse: Houston ranks as only No. 10 on the report's Best Place to Live in Texas list for 2023.

Texas overall saw a major drop. Austin, previously the No. 1 place to live in America for three consecutive years from 2017 to 2019, lands at No. 40 overall this year. Austin managed to hang on to its title of the Best Place to Live in Texas for 2023, with San Antonio at No. 2, and Dallas-Fort Worth taking No. 3. Rounding out the top five is Killeen in No. 4, and El Paso at No. 5.

Here's how other Texas cities faired in 2023's Best Places to Live report:

  • No. 103 – San Antonio, down from No. 83 last year
  • No. 113 – Dallas-Fort Worth, down from No. 32 last year
  • No. 122 – Killeen, down from No. 108 last year
  • No. 128 – El Paso, down from No. 124 last year
  • No. 131 – Beaumont, down from No. 109 last year
  • No. 132 – Corpus Christi, up from No. 133 last year
  • No. 134 – Brownsville, unchanged from last year
  • No. 137 – McAllen, up from No. 138 last year
  • No. 140 – Houston, down from No. 59 last year

The full report can be found on U.S. News and World Report's website.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”